Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins

Andreas Engert, Claudia Gottstein, Ute Winkler, Peter Amlot, Stefano Pileri, Volker Diehl, Philip Thorpe

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In the present paper we describe the evaluation of ricin A-chain immunotoxins for clinical application in Hodgkin's disease. The immunotoxins were constructed by chemically linking deglycosylated ricin-A to monoclonal antibodies (MoAb) recognising lymphocyte activation markers CD25, CD30, or IRac, which are expressed by Hodgkin's and Reed-Sternberg (H-RS) cells. The cytotoxic effects of the immunotoxins were investigated in vitro against L540Cy Hodgkin cells and in vivo against Hodgkin's tumors in nude mice and disseminated Hodgkin's tumors in SCID mice. MoAbs were evaluated for crossreactivity with normal human tissues and staining of sections from Hodgkin's disease tissue. Of 32 MoAbs, eight showed little crossreactivity with vital human organs and produced highly active immunotoxins. The most effective immunotoxin, RFT5γ1.dgA (CD25), inhibits the growth of H-RS cells at concentrations of 7 × 10-12 M. RFT5γ1.dgA destroys about 60% of solid Hodgkin's tumors of 0.5 cm diameter in nude mice and induces complete remissions in 95% of SCID mice with disseminated Hodgkin's tumors when administered one day after tumor challenge. This immunotoxin binds to all H-RS cells in more than 90% of patients with Hodgkin's disease. Patients with refractory Hodgkin's disease are currently being treated in a phase-I/II clinical trial.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalLeukemia and Lymphoma
Volume13
Issue number5-6
DOIs
StatePublished - 1994

Fingerprint

Ricin
Immunotoxins
Hodgkin Disease
Reed-Sternberg Cells
Therapeutics
SCID Mice
Neoplasms
Nude Mice
Phase II Clinical Trials
Clinical Trials, Phase I
Lymphocyte Activation

Keywords

  • Hodgkin's disease
  • Immunotoxin
  • Treatment ricin-A chain

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Engert, A., Gottstein, C., Winkler, U., Amlot, P., Pileri, S., Diehl, V., & Thorpe, P. (1994). Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins. Leukemia and Lymphoma, 13(5-6), 441-448. https://doi.org/10.3109/10428199409049633

Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins. / Engert, Andreas; Gottstein, Claudia; Winkler, Ute; Amlot, Peter; Pileri, Stefano; Diehl, Volker; Thorpe, Philip.

In: Leukemia and Lymphoma, Vol. 13, No. 5-6, 1994, p. 441-448.

Research output: Contribution to journalArticle

Engert, A, Gottstein, C, Winkler, U, Amlot, P, Pileri, S, Diehl, V & Thorpe, P 1994, 'Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins', Leukemia and Lymphoma, vol. 13, no. 5-6, pp. 441-448. https://doi.org/10.3109/10428199409049633
Engert, Andreas ; Gottstein, Claudia ; Winkler, Ute ; Amlot, Peter ; Pileri, Stefano ; Diehl, Volker ; Thorpe, Philip. / Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins. In: Leukemia and Lymphoma. 1994 ; Vol. 13, No. 5-6. pp. 441-448.
@article{2ccd1e5894254e49b712ec92bdecd616,
title = "Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins",
abstract = "In the present paper we describe the evaluation of ricin A-chain immunotoxins for clinical application in Hodgkin's disease. The immunotoxins were constructed by chemically linking deglycosylated ricin-A to monoclonal antibodies (MoAb) recognising lymphocyte activation markers CD25, CD30, or IRac, which are expressed by Hodgkin's and Reed-Sternberg (H-RS) cells. The cytotoxic effects of the immunotoxins were investigated in vitro against L540Cy Hodgkin cells and in vivo against Hodgkin's tumors in nude mice and disseminated Hodgkin's tumors in SCID mice. MoAbs were evaluated for crossreactivity with normal human tissues and staining of sections from Hodgkin's disease tissue. Of 32 MoAbs, eight showed little crossreactivity with vital human organs and produced highly active immunotoxins. The most effective immunotoxin, RFT5γ1.dgA (CD25), inhibits the growth of H-RS cells at concentrations of 7 × 10-12 M. RFT5γ1.dgA destroys about 60{\%} of solid Hodgkin's tumors of 0.5 cm diameter in nude mice and induces complete remissions in 95{\%} of SCID mice with disseminated Hodgkin's tumors when administered one day after tumor challenge. This immunotoxin binds to all H-RS cells in more than 90{\%} of patients with Hodgkin's disease. Patients with refractory Hodgkin's disease are currently being treated in a phase-I/II clinical trial.",
keywords = "Hodgkin's disease, Immunotoxin, Treatment ricin-A chain",
author = "Andreas Engert and Claudia Gottstein and Ute Winkler and Peter Amlot and Stefano Pileri and Volker Diehl and Philip Thorpe",
year = "1994",
doi = "10.3109/10428199409049633",
language = "English (US)",
volume = "13",
pages = "441--448",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Experimental treatment of human hodgkin's disease with ricin a-chain immunotoxins

AU - Engert, Andreas

AU - Gottstein, Claudia

AU - Winkler, Ute

AU - Amlot, Peter

AU - Pileri, Stefano

AU - Diehl, Volker

AU - Thorpe, Philip

PY - 1994

Y1 - 1994

N2 - In the present paper we describe the evaluation of ricin A-chain immunotoxins for clinical application in Hodgkin's disease. The immunotoxins were constructed by chemically linking deglycosylated ricin-A to monoclonal antibodies (MoAb) recognising lymphocyte activation markers CD25, CD30, or IRac, which are expressed by Hodgkin's and Reed-Sternberg (H-RS) cells. The cytotoxic effects of the immunotoxins were investigated in vitro against L540Cy Hodgkin cells and in vivo against Hodgkin's tumors in nude mice and disseminated Hodgkin's tumors in SCID mice. MoAbs were evaluated for crossreactivity with normal human tissues and staining of sections from Hodgkin's disease tissue. Of 32 MoAbs, eight showed little crossreactivity with vital human organs and produced highly active immunotoxins. The most effective immunotoxin, RFT5γ1.dgA (CD25), inhibits the growth of H-RS cells at concentrations of 7 × 10-12 M. RFT5γ1.dgA destroys about 60% of solid Hodgkin's tumors of 0.5 cm diameter in nude mice and induces complete remissions in 95% of SCID mice with disseminated Hodgkin's tumors when administered one day after tumor challenge. This immunotoxin binds to all H-RS cells in more than 90% of patients with Hodgkin's disease. Patients with refractory Hodgkin's disease are currently being treated in a phase-I/II clinical trial.

AB - In the present paper we describe the evaluation of ricin A-chain immunotoxins for clinical application in Hodgkin's disease. The immunotoxins were constructed by chemically linking deglycosylated ricin-A to monoclonal antibodies (MoAb) recognising lymphocyte activation markers CD25, CD30, or IRac, which are expressed by Hodgkin's and Reed-Sternberg (H-RS) cells. The cytotoxic effects of the immunotoxins were investigated in vitro against L540Cy Hodgkin cells and in vivo against Hodgkin's tumors in nude mice and disseminated Hodgkin's tumors in SCID mice. MoAbs were evaluated for crossreactivity with normal human tissues and staining of sections from Hodgkin's disease tissue. Of 32 MoAbs, eight showed little crossreactivity with vital human organs and produced highly active immunotoxins. The most effective immunotoxin, RFT5γ1.dgA (CD25), inhibits the growth of H-RS cells at concentrations of 7 × 10-12 M. RFT5γ1.dgA destroys about 60% of solid Hodgkin's tumors of 0.5 cm diameter in nude mice and induces complete remissions in 95% of SCID mice with disseminated Hodgkin's tumors when administered one day after tumor challenge. This immunotoxin binds to all H-RS cells in more than 90% of patients with Hodgkin's disease. Patients with refractory Hodgkin's disease are currently being treated in a phase-I/II clinical trial.

KW - Hodgkin's disease

KW - Immunotoxin

KW - Treatment ricin-A chain

UR - http://www.scopus.com/inward/record.url?scp=0028206212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028206212&partnerID=8YFLogxK

U2 - 10.3109/10428199409049633

DO - 10.3109/10428199409049633

M3 - Article

C2 - 8069189

AN - SCOPUS:0028206212

VL - 13

SP - 441

EP - 448

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -